- Home
- BORR vs TSHA Comparison
BORR vs TSHA Comparison
Compare BORR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BORR | TSHA |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BORR | TSHA |
|---|---|---|
| Price | $5.49 | $4.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $4.60 | ★ $10.56 |
| AVG Volume (30 Days) | ★ 6.2M | 2.6M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,024,500,000.00 | $6,310,000.00 |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.07 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $1.55 | $1.05 |
| 52 Week High | $5.68 | $6.02 |
Technical Indicators
Market Signals| Indicator | BORR | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 72.50 | 43.08 |
| Support Level | $4.81 | $4.40 |
| Resistance Level | $5.68 | $4.70 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 85.45 | 13.10 |
Price Performance
Historical ComparisonAbout BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.